Sulforaphane attenuates activation of NLRP3 and NLRC4 inflammasomes but not AIM2 inflammasome

Cellular Immunology

Volumn 306-307, Issue , 2016, Pages 53-60

  Lee, Jiseon ^a   Ahn, Huijeong ^a   Hong, Eui Ju ^b   An, Beum Soo ^c   Jeung, Eui Bae ^d   Lee, Geun Shik ^a  

^a Kangwon National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Pusan National University   (South Korea)

^d Chungbuk National University   (South Korea)

Author keywords

AIM2; Inflammasome; NLRC4; NLRP3; Sulforaphane

Indexed keywords

ADENOSINE TRIPHOSPHATE; AIM2 PROTEIN; CRYOPYRIN; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; NIGERICIN; NLRC4 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; ROTENONE; SULFORAPHANE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URIC ACID; AIM2 PROTEIN, MOUSE; ANTIINFLAMMATORY AGENT; APOPTOSIS REGULATORY PROTEIN; CALCIUM BINDING PROTEIN; DNA BINDING PROTEIN; IPAF PROTEIN, MOUSE; ISOTHIOCYANIC ACID DERIVATIVE; NLRP3 PROTEIN, MOUSE; SULFORAFAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; INOCULATION; LISTERIA MONOCYTOGENES; MACROPHAGE; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PERITONEAL EXUDATE CELL; PERITONITIS; PRIORITY JOURNAL; PYROPTOSIS; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; UPREGULATION; ANIMAL; BRASSICACEAE; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MITOCHONDRION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS REGULATORY PROTEINS; BRASSICACEAE; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; ISOTHIOCYANATES; MACROPHAGES; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PERITONITIS; URIC ACID;

EID: 84979598075     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2016.07.007     Document Type: Article

References (42)

1. [1] Schroder, K., Zhou, R., Tschopp, J., The NLRP3 inflammasome: a sensor for metabolic danger?. Science 327 (2010), 296–300.
2. [2] Lee, G.S., Inflammasomes, multi-cellular protein complex in myeloid cells, induce several metabolic diseases via interleukin-1β maturation. J. Biomed. Res. 14 (2013), 195–200.
3. [3] Fahey, J.W., Zhang, Y., Talalay, P., Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. U.S.A. 94 (1997), 10367–10372.
4. [4] Lin, W., Wu, R.T., Wu, T., Khor, T.O., Wang, H., Kong, A.N., Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol. 76 (2008), 967–973.
5. [5] Sun, C.C., Li, S.J., Yang, C.L., Xue, R.L., Xi, Y.Y., Wang, L., Zhao, Q.L., Li, D.J., Sulforaphane attenuates muscle inflammation in dystrophin-deficient mdx Mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-kappaB signaling pathway. J. Biol. Chem. 290 (2015), 17784–17795.
6. [6] Folkard, D.L., Melchini, A., Traka, M.H., Al-Bakheit, A., Saha, S., Mulholland, F., Watson, A., Mithen, R.F., Suppression of LPS-induced transcription and cytokine secretion by the dietary isothiocyanate sulforaphane. Mol. Nutr. Food Res. 58 (2014), 2286–2296.
7. [7] Greaney, A.J., Maier, N.K., Leppla, S.H., Moayeri, M., Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J. Leukoc. Biol., 2015.
8. [8] Folkard, D.L., Marlow, G., Mithen, R.F., Ferguson, L.R., Effect of Sulforaphane on NOD2 via NF-kappaB: implications for Crohn's disease. J. Inflamm. (Lond.), 12, 2015, 6.
9. [9] Kim, H.V., Kim, H.Y., Ehrlich, H.Y., Choi, S.Y., Kim, D.J., Kim, Y., Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 20 (2013), 7–12.
10. [10] Kim, J., Ahn, H., Woo, H.M., Lee, E., Lee, G.S., Characterization of porcine NLRP3 inflammasome activation and its upstream mechanism. Vet. Res. Commun. 38 (2014), 193–200.
11. [11] Englen, M.D., Valdez, Y.E., Lehnert, N.M., Lehnert, B.E., Granulocyte/macrophage colony-stimulating factor is expressed and secreted in cultures of murine L929 cells. J. Immunol. Methods 184 (1995), 281–283.
12. [12] Boltz-Nitulescu, G., Wiltschke, C., Holzinger, C., Fellinger, A., Scheiner, O., Gessl, A., Forster, O., Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant. J. Leukoc. Biol. 41 (1987), 83–91.
13. 2+ and cAMP. Nature 492 (2012), 123–127.
14. [14] Fernandes-Alnemri, T., Yu, J.W., Juliana, C., Solorzano, L., Kang, S., Wu, J., Datta, P., McCormick, M., Huang, L., McDermott, E., Eisenlohr, L., Landel, C.P., Alnemri, E.S., The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat. Immunol. 11 (2010), 385–393.
15. [15] Fahey, J.W., Talalay, P., Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem. Toxicol. 37 (1999), 973–979.
16. [16] Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., Gerhauser, C., Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276 (2001), 32008–32015.
17. [17] Zhang, Y., Tang, L., Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol. Sin. 28 (2007), 1343–1354.
18. [18] Liu, H., Talalay, P., Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 19065–19070.
19. [19] Kim, S., Bauernfeind, F., Ablasser, A., Hartmann, G., Fitzgerald, K.A., Latz, E., Hornung, V., Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur. J. Immunol. 40 (2010), 1545–1551.
20. [20] Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Nunez, G., Hornung, V., Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187 (2011), 613–617.
21. [21] Bauernfeind, F.G., Horvath, G., Stutz, A., Alnemri, E.S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B.G., Fitzgerald, K.A., Hornung, V., Latz, E., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183 (2009), 787–791.
22. [22] Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006), 237–241.
23. [23] Zhou, R., Yazdi, A.S., Menu, P., Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (2011), 221–225.
24. [24] Ahn, H., Kim, J., Lee, M.J., Kim, Y.J., Cho, Y.W., Lee, G.S., Methylsulfonylmethane inhibits NLRP3 inflammasome activation. Cytokine 71 (2015), 223–231.
25. [25] Cassel, S.L., Eisenbarth, S.C., Iyer, S.S., Sadler, J.J., Colegio, O.R., Tephly, L.A., Carter, A.B., Rothman, P.B., Flavell, R.A., Sutterwala, F.S., The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 9035–9040.
26. [26] Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., Tschopp, J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008), 674–677.
27. [27] Zhou, R., Tardivel, A., Thorens, B., Choi, I., Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140.
28. [28] Maier, N.K., Crown, D., Liu, J., Leppla, S.H., Moayeri, M., Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes. J. Immunol. 192 (2014), 763–770.
29. [29] Reddy, S.A., Shelar, S.B., Dang, T.M., Lee, B.N., Yang, H., Ong, S.M., Ng, H.L., Chui, W.K., Wong, S.C., Chew, E.H., Sulforaphane and its methylcarbonyl analogs inhibit the LPS-stimulated inflammatory response in human monocytes through modulating cytokine production, suppressing chemotactic migration and phagocytosis in a NF-kappaB- and MAPK-dependent manner. Int. Immunopharmacol. 24 (2015), 440–450.
30. [30] Youn, H.S., Kim, Y.S., Park, Z.Y., Kim, S.Y., Choi, N.Y., Joung, S.M., Seo, J.A., Lim, K.M., Kwak, M.K., Hwang, D.H., Lee, J.Y., Sulforaphane suppresses oligomerization of TLR4 in a thiol-dependent manner. J. Immunol. 184 (2010), 411–419.
31. [31] Davis, B.K., Wen, H., Ting, J.P., The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29 (2011), 707–735.
32. [32] Walsh, J.G., Reinke, S.N., Mamik, M.K., McKenzie, B.A., Maingat, F., Branton, W.G., Broadhurst, D.I., Power, C., Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology, 11, 2014, 35.
33. [33] Broderick, L., De Nardo, D., Franklin, B.S., Hoffman, H.M., Latz, E., The inflammasomes and autoinflammatory syndromes. Annu. Rev. Pathol. 10 (2015), 395–424.
34. [34] Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M.T., Zhang, C., Chen, Q., Tan, Y., Cui, T., Zheng, Y., Cai, L., Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell. Cardiol. 57 (2013), 82–95.
35. [35] Wang, Y., Zhang, Z., Sun, W., Tan, Y., Liu, Y., Zheng, Y., Liu, Q., Cai, L., Sun, J., Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function. Oxid. Med. Cell. Longevity, 2014, 2014, 123963.
36. [36] Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., An, F., NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One, 9, 2014, e104771.
37. [37] Nguyen, B., Luong, L., Naase, H., Vives, M., Jakaj, G., Finch, J., Boyle, J., Mulholland, J.W., Kwak, J.H., Pyo, S., de Luca, A., Athanasiou, T., Angelini, G., Anderson, J., Haskard, D.O., Evans, P.C., Sulforaphane pretreatment prevents systemic inflammation and renal injury in response to cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 148 (2014), 690–697 e693.
38. [38] Komada, T., Usui, F., Kawashima, A., Kimura, H., Karasawa, T., Inoue, Y., Kobayashi, M., Mizushina, Y., Kasahara, T., Taniguchi, S., Muto, S., Nagata, D., Takahashi, M., Role of NLRP3 inflammasomes for rhabdomyolysis-induced Acute Kidney Injury. Sci. Rep., 5, 2015, 10901.
39. [39] Bauer, C., Duewell, P., Mayer, C., Lehr, H.A., Fitzgerald, K.A., Dauer, M., Tschopp, J., Endres, S., Latz, E., Schnurr, M., Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59 (2010), 1192–1199.
40. [40] Wagner, A.E., Will, O., Sturm, C., Lipinski, S., Rosenstiel, P., Rimbach, G., DSS-induced acute colitis in C57BL/6 mice is mitigated by sulforaphane pre-treatment. J. Nutr. Biochem. 24 (2013), 2085–2091.
41. [41] Zhang, R., Zhang, J., Fang, L., Li, X., Zhao, Y., Shi, W., An, L., Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions. Int. J. Mol. Sci. 15 (2014), 14396–14410.
42. [42] Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.C., Gelpi, E., Halle, A., Korte, M., Latz, E., Golenbock, D.T., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493 (2013), 674–678.